# Ex vivo cell expansion

Source: https://onco.cc/terms/ex-vivo-cell-expansion/  
OnCo record `ex-vivo-cell-expansion` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cell expansion increases the number of a defined group of living cells outside the body. Selecting cells or activating them answers a different question.

## Summary

Expansion compares absolute counts of a specified living population at stated points in a culture process. Enrichment or selection changes mixture composition, while activation changes cellular state. Measurements need a consistent cell definition, viability basis, sampling method and interval. Cell concentration can change with dilution or volume, and a higher fraction can result from losing other cells rather than producing more intended cells.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: cell culture expansion; fold expansion; cell enrichment versus expansion

## Notes

- In a fictional mixture, 20 million intended cells and 80 million other cells become 20 million intended and five million other cells after enrichment. The intended fraction rises from 20/100 to 20/25 without increasing the intended-cell count. In a separate culture example, 20 million viable intended cells becoming 100 million is five-fold expansion. These are invented arithmetic examples, not process-performance targets.
- Culture conditions, activation, gene transfer, duration, selection and preservation can change subsets, differentiation, viability and function. A greater count does not establish equal starting-cell quality, a favourable state or greater tumour killing. Activation markers and intended biological activity require suitable separate measurements.
- Ghassemi's 2018 study compared shorter and longer preparation in human CAR T-cell experiments, a mouse acute-lymphoblastic-leukaemia model and manufacturing-feasibility work. The reported culture comparison does not prove that every shorter process improves human outcomes or specify one optimal duration for all products.
- Dupouy's adult CALM analysis distinguishes factory fold expansion from later blood transgene and flow-cytometry kinetics. In-body detection depends on sampling, proliferation, distribution, loss and expression. A blood copy count is not an absolute whole-body count or a direct functional assay.
- Expansion can be one input to a product-specific control strategy. It does not replace identity, purity, viability, potency, contamination testing, lot disposition or clinical readiness. Manufacturing yield, culture time, collection-to-infusion time and patient benefit remain separate outcomes.

## Sources

- FDA: CAR T-cell development guidance, January 2024: https://www.fda.gov/media/156896/download
- Ghassemi et al., 2018: defined culture-duration comparisons and mouse experiments: https://pubmed.ncbi.nlm.nih.gov/30030295/
- Dupouy et al., 2022: factory expansion and adult CALM cellular kinetics: https://pubmed.ncbi.nlm.nih.gov/36970059/

## Connected records

- technologies: [Autologous CAR-T manufacturing, batch by batch](https://onco.cc/technologies/car-t-manufacturing-process/), [Cryopreservation and cell-therapy cold chain](https://onco.cc/technologies/cell-therapy-cold-chain/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- terms: [Apheresis (leukapheresis)](https://onco.cc/terms/apheresis/), [Cell-manufacturing outcomes and nonconforming products](https://onco.cc/terms/cell-manufacturing-outcomes/), [Cellular kinetics and persistence](https://onco.cc/terms/cellular-kinetics-and-persistence/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)

---
JSON: https://onco.cc/api/v1/entities/ex-vivo-cell-expansion.json